Luxembourg vs Portugal: Prevalence rate of obesity in adults
Luxembourg
19.0%
in 2024
Portugal
18.1%
in 2024
Luxembourg rank
126th
Portugal rank
128th
Prevalence rate of obesity in adults over time
- Luxembourg
- Portugal
How they compare
Luxembourg currently reports 19.0% against 18.1% in Portugal, a difference of 0.9%.
That makes Luxembourg's figure about 1.1 times Portugal's.
The two have swapped places 3 times across 45 shared years of data; in 1980 it was Portugal ahead.
Luxembourg ranks 126th and Portugal ranks 128th of 199 countries.
Across the 5 decades both report, Luxembourg averaged higher in 2 and Portugal in 3.
Head to head by decade
| Decade | Luxembourg | Portugal | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 11.2% | 11.7% | 0.4% | Portugal |
| 1990s | 13.9% | 13.5% | 0.3% | Luxembourg |
| 2000s | 17.1% | 17.2% | 0.1% | Portugal |
| 2010s | 18.3% | 18.9% | 0.6% | Portugal |
| 2020s | 18.8% | 18.3% | 0.5% | Luxembourg |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of obesity in adults, Luxembourg or Portugal?
- Luxembourg, at 19.0% against 18.1% in Portugal as of 2024.
- What is the difference in prevalence rate of obesity in adults between Luxembourg and Portugal?
- 0.9%, with Luxembourg ahead.
- How many years of comparable data are there for Luxembourg and Portugal?
- 45 years are reported by both, from 1980 to 2024.
- How do Luxembourg and Portugal rank globally for prevalence rate of obesity in adults?
- Luxembourg ranks 126th and Portugal ranks 128th of 199 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) β with minor processing by Our World in Data, published as Prevalence rate of obesity in adults. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated prevalence of obesity in adults, based on general population surveys and statistical modeling. Obesity is a risk factor for chronic complications, including cardiovascular disease, and premature death.